YOLFTbeta
Abionyx Pharma SA

Abionyx Pharma SA

ABNX · PA · Healthcare / Biotechnology

1.67EUR-0.03 (-1.76%)

Price History

Full chart

Market Stats

Previous Close1.70
Open1.68
Day Range1.65 – 1.74
52-Week Range1.61 – 5.21
Volume136.44K
Market Cap70.57M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.22
Dividend Yield0.00%
Beta0.46
50-Day Avg1.89
200-Day Avg2.88

About

ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States. It operates through Research and Development Activities for the Development of Innovative Drugs; and Contract Research Organization (CRO) Activities segments. The company develops CER-001, a recombinant HDL mimetic biopharmaceutical in a Phase III trial for the treatment of lecithin cholesterol acyltransferase (LCAT) deficiency, as well as in a Phase II trial for the treatment of sepsis. It is also developing ABNX-100, a strategic extension into ophthalmology of CER-001 that is in preclinical trial for the treatment of uveitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was incorporated in 2005 and is headquartered in Balma, France.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOSir Cyrille Tupin CPA
  • Employees49
  • HeadquartersBuilding D2, Balma, France, 31130, France
  • Websitehttps://abionyx.com

Leadership

  • Sir Cyrille Tupin CPACEO, GM & Director · b. 1977
  • Prof. Christian Chavy MBAIndependent Director · b. 1950
  • Mr. Emmanuel De FougerouxAdministrative & Financial Director
  • Ms. Constance Keyserling Peyrottes M.S.Vice President of Clinical, Regulatory Development & Operations · b. 1961
  • Mr. Laurent GuerciChief Digital & Innovation Officer

Financials

Income Statement

Currency: EUR2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue---00174.00K00675.00K5.25M4.64M4.60M4.06M
Growth (%)-------100.00%--+678.07%-11.65%-0.86%-11.67%
Cost of Revenue--55.00K53.00K43.00K072.00K80.00K416.00K4.62M4.02M3.70M3.69M
Gross Profit---55.00K-53.00K-43.00K174.00K-72.00K-80.00K259.00K636.00K618.00K844.00K376.00K
Gross Margin-----100.00%--38.37%12.11%13.32%18.35%9.25%
Operating Expense--15.42M23.98M6.59M7.23M2.45M3.50M6.21M4.75M4.03M6.42M6.63M
Operating Income-9.81M-6.07M-15.47M-24.04M-6.64M-7.05M-2.52M-3.58M-5.95M-4.11M-3.41M-5.57M-6.25M
Operating Margin------4052.87%---881.78%-78.24%-73.53%-121.13%-153.95%
EBITDA-9.27M-6.77M-17.30M-26.95M-5.80M-6.26M1.80M-2.33M-7.42M-4.01M-4.53M-4.93M-5.70M
EBITDA Margin------3600.57%---1098.96%-76.35%-97.65%-107.13%-140.39%
Net Income-7.74M-6.56M-16.64M-24.87M-4.98M-6.30M1.85M-1.89M-5.82M-4.21M-3.52M-4.40M-5.55M
Net Income Margin------3623.56%---862.52%-80.08%-75.82%-95.65%-136.60%
R&D8.88M4.28M14.66M17.00M6.31M4.29M744.00K2.31M5.68M2.56M2.90M2.99M1.50M
R&D as % of Total Revenue-----2468.39%--841.04%48.80%62.54%64.91%36.92%
Interest Expense210.00K918.00K1.22M1.26M167.00K148.00K350.00K95.00K124.00K240.00K19.00K61.00K200.00K
Interest Expense % of Total Revenue-----85.06%--18.37%4.57%0.41%1.33%4.92%

Balance Sheet

Currency: EUR2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets13.93M10.84M46.11M29.07M18.30M13.13M10.25M10.29M21.83M15.82M14.83M13.45M12.86M
Total Liabilities7.76M10.82M12.91M14.46M9.41M9.30M3.58M3.66M11.15M8.65M6.91M6.03M8.60M
Total Equity6.16M12.00K33.20M14.61M8.89M3.84M6.67M6.63M10.68M7.17M7.92M7.42M4.26M
Cash11.14M7.84M42.95M24.68M16.27M11.46M8.33M9.15M7.93M4.05M4.10M3.23M3.52M
Total Debt4.05M4.99M6.09M7.05M6.22M5.50M1.18M24.00K4.96M4.01M3.39M3.10M3.81M
Net Debt-7.09M-2.85M-36.86M-17.92M-10.05M-5.95M-7.15M-9.13M-2.98M-33.00K-714.00K-137.00K284.00K

Cash Flow

Currency: EUR2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-14.49M-3.30M-13.71M-19.20M-9.09M-6.00M-3.95M-599.00K-6.69M-3.36M-3.70M-3.60M-2.93M
Investing Cash Flow-8.00K1.00K-171.00K-5.00K-213.00K-10.00K-100.00K-125.00K1.34M-175.00K-130.00K-100.00K-205.00K
Financing Cash Flow-750.00K-48.99M925.00K902.00K1.20M823.00K1.55M3.97M-194.00K3.89M2.80M3.42M
Capital Expenditure8.00K3.00K171.00K5.00K213.00K23.00K103.00K148.00K166.00K175.00K130.00K76.00K242.00K
Free Cash Flow-14.50M-3.31M-13.88M-19.20M-9.30M-6.02M-3.95M-747.00K-6.86M-3.53M-3.83M-3.60M-3.17M
Dividends Paid-------1.55M3.97M----
FCF to OCF100.06%100.09%101.25%100.03%102.34%100.38%100.00%124.71%102.48%105.21%103.52%100.00%108.25%
Dividend Paid to FCF--------207.10%-57.92%----

Earnings

Report DateNov 7, 2016Sep 12, 2017Feb 2, 2018Apr 19, 2018Sep 10, 2018Nov 28, 2018Jan 24, 2019Apr 29, 2019Sep 6, 2019Oct 24, 2019Mar 10, 2020Apr 23, 2020Sep 10, 2020Oct 22, 2020Feb 25, 2021May 6, 2021Aug 5, 2021Nov 4, 2021Apr 29, 2022Aug 18, 2022Nov 17, 2022Mar 29, 2023May 17, 2023Aug 17, 2023Nov 21, 2023Mar 11, 2024May 16, 2024Sep 26, 2024Nov 14, 2024Mar 17, 2025May 28, 2025Sep 25, 2025Nov 25, 2025
EPS Estimate0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00-0.100.000.00-0.000.000.000.000.000.000.000.000.000.000.00-0.00
EPS Actual0.00-0.04-0.230.00-0.190.00-0.150.000.150.00-0.050.00-0.040.00-0.040.00-0.100.00-0.13-0.090.00-0.060.000.000.000.000.000.000.00-0.070.00-0.030.00
Surprise----------------0.00%----------------
TimingPre-marketAfter-hoursAfter-hoursPre-marketPre-market-After-hoursAfter-hoursAfter-hours-After-hours-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursPre-marketPre-market-----Pre-market-

Key Statistics & Ratios

Market Cap70.57M
Enterprise Value80.78M
Trailing P/E0.00
Forward P/E0.00
Price / Sales17.37
Price / Book17.84
EPS-0.22
Book Value0.128
Revenue (TTM)4.06M
Gross Profit (TTM)534.00K
EBITDA-5.42M
Profit Margin-136.60%
Operating Margin-165.02%
Return on Equity-92.29%
Return on Assets-25.97%
Shares Outstanding43.51M
Shares Float22.34M
Beta0.46
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • May 29, 202666:65